BioGenomics

Biogenomics is a science-driven, vertically integrated pharmaceutical company specializing in treatments for diabetes and oncology. Backed by Oman Investment Authority and guided by a team of distinguished scientists, business leaders, and experts in molecular biology, microbiology, and protein engineering, Biogenomics has in a short span of time has developed a wide portfolio of biosimilars and biotech products. As an industry pioneer, Biogenomics became the first company in India to successfully launch a biosimilar of Insulin Aspart. With a robust pipeline, the company has several additional products awaiting approval. Committed to enhancing patient outcomes globally, Biogenomics has an active clinical development program focused on advancing chemical entities and biologics for the treatment of diabetes, cancer, and other critical therapeutic areas. As a young, fast-growing biopharmaceutical firm, Biogenomics is on a path to delivering excellence in healthcare. Our mission is to enrich lives by providing high-quality, affordable drugs, ensuring patient access to expensive specialty pharmaceuticals and biologic treatments. With two new additional manufacturing facilities coming up in India and Oman, Biogenomics is poised for significant global expansion. Beginning filings in 2025, the company plans to extend its reach into North America, Europe, and other key markets, further solidifying its international presence.